Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Chosa

    MCap

    SEK57m

    Last close

    SEK0.80

    ▲ 0.20 (33.33%)

    Vection Technologies

    MCap

    AUD47m

    Last close

    AUD0.04

    ▲ 0.00 (12.90%)

    Metro Bank

    MCap

    GBP684m

    Last close

    GBP1.02

    ▲ 7.90 (8.43%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Molecure – executive interview with Marcin Szumowski, CEO

Molecure – executive interview with Marcin Szumowski, CEO

Molecure — 2 videos in collection

More on this equity

Molecure is a clinical-stage biotechnology company focused on medicinal chemistry and biology capabilities to discover and develop first-in-class small molecule drug candidates that directly modulate the function of RNA and underexplored protein targets designed to treat multiple incurable diseases. Molecure is entering FY23 with two active clinical programmes. OATD-01, the company’s lead proprietary asset, is in development for the treatment of sarcoidosis, but management expects to expand into new indications if the data are supportive. Molecure also recently reported the first dosing in the Phase I trial for OATD-02, a novel drug for the treatment of solid tumours; an update for this study is expected in Q423.

In this video, Marcin Szumowski, Molecure’s CEO, provides background on the company’s developmental pipeline, highlighting the near-term priorities and plans.

< Previous
Next >

You may also be interested in these:

Healthcare

Molecure – executive interview with Dr Samson Fung, Chief Medical Officer

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free